CTOR
Citius Oncology, Inc. - Common Stock (CTOR)
$12
About Citius Oncology, Inc. - Common Stock (CTOR)
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Details
Daily high
$1.15
Daily low
$1.08
Price at open
$1.15
52 Week High
$2.25
52 Week Low
$0.49
Market cap
106.0M
Dividend yield
-
Volume
40,631
Avg. volume
89,380
P/E ratio
-2.41
Citius Oncology, Inc. - Common Stock News
Details
Daily high
$1.15
Daily low
$1.08
Price at open
$1.15
52 Week High
$2.25
52 Week Low
$0.49
Market cap
106.0M
Dividend yield
-
Volume
40,631
Avg. volume
89,380
P/E ratio
-2.41